Peptide Vaccines and Antigens
5 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- CYT006-AngQbCYT006‑AngQb is an investigational vaccine that couples angiotensin II to virus‑like particles. It is designed to stimulate the immune system to produce antibodies that neutralise circulating angiotensin II, thereby lowering blood pressure in people with hypertension.
- DirucotideDirucotide (MBP8298) is a synthetic myelin basic protein peptide fragment investigated as a disease-modifying agent for secondary progressive multiple sclerosis (SPMS). It aimed to induce immune tolerance against myelin antigens. Phase III trials (MAESTRO-03) failed to meet primary endpoints, halting further development.
- G17DT ImmunogenG17DT immunogen is a synthetic peptide vaccine that couples gastrin‑17 to diphtheria toxoid, prompting the body to generate high‑affinity antibodies against gastrin‑17. It is being investigated as an adjunct treatment for gastrointestinal malignancies, including metastatic colorectal cancer and gastric type I carcinoid, where gastrin‑driven growth may contribute to tumor progression.
- Nelipepimut-SNelipepimut‑S (also called E75 or NeuVax) is a synthetic peptide derived from the HER2/neu protein, formulated with the immune‑stimulating cytokine GM‑CSF. It is being investigated as a cancer vaccine intended to provoke HER2‑specific cytotoxic T‑cell responses that could prevent recurrence of breast cancer, particularly in patients whose tumours express low levels of HER2 or in the pre‑operative setting, or as an adjuvant after standard therapy.
- VEGFR2-169VEGFR2-169 is a synthetic peptide vaccine that targets the vascular endothelial growth factor receptor‑2 (VEGFR2), a protein over‑expressed on tumor‑associated blood vessels. Developed as an investigational cancer immunotherapy, it is administered by subcutaneous (or intramuscular) injection, often in combination with standard chemotherapy, to stimulate a cytotoxic T‑cell response against VEGFR2‑expressing endothelial cells and inhibit tumor angiogenesis, and may improve disease control in advanced pancreatic and gastric cancers.